Gain Therapeutics’ Post

Check out how Halia Therapeutics, Inc. is approaching Parkinson’s disease and other inflammatory conditions in this article from BioSpace

⚡ Cell-type-specific Alzheimer’s disease polygenic risk scores are associated with distinct disease processes in Alzheimer’s disease | Nature Discover more at "voltsbase.com/energy" #Energy #Voltsbase

Inflammation in osteoarthritis: Our view on its presence and involvement in disease development over the years https://bit.ly/3vNfy3h #Osteoarthritis #KneeOsteoarthritis #OA

#ICYMI...Calling all KOL's, Analysts, Patient Advocates and Investors who share a common interest in #neurodegenerativediseases. Please join us for our R&D update next Thursday. "Beyond Symptomatic Treatment of #Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024" Date: February 22nd, 2024 Time: 11:00 am - 12:00 pm EST Register for the Event here: https://lnkd.in/erx-c4vn Send any questions you’d like answered in our Q&A to ir@gaintherapeutics.com. Discussion Topics GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies. From biology to classification: understanding Parkinson’s Disease. Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases. Speakers Gain Therapeutics Matthias Alder - Chief Executive Officer Joanne Taylor – Senior Vice President, Research Key Opinion Leaders Professor Roy Alcalay Prof. Alcalay is Chief of the Movement Disorders Division at Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. He also holds an associate professorship in clinical neurology at Columbia University. His research focuses on biomarkers and genetics in Parkinson’s Disease. He is a member of The Michael J. Fox Foundation for Parkinson's Research-funded Parkinson’s Progression Markers Initiative (PPMI) executive steering committee, and the PI of the Parkinson’s Foundation-funded PD GENEration study. Professor Tiago Fleming Outeiro Prof. Outeiro is Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen in Germany. He is also Professor at Newcastle University. His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease. He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Based on these data, the phase 2 Regenerate PD trial of AB-1005 will begin enrolling later this year for #Parkinson disease. https://lnkd.in/eC6P-fW5

Our new article is out in the Journal of Inflammation! Read it if you'd like to know more about the role of capsaicin in inflammation. 🌶 https://lnkd.in/gZr76-sX

Interesting read… moderate-intensity exercise for ≥30 minutes, ≥4 days per week or strenuous-intensity exercise for 20 minutes, ≥2 days per week) reduces mortality risk.

Tight junction and kidney stone disease https://lnkd.in/eZKs3c4K

Ceria aims to transform the lives of patients with inflammatory disorders by eliminating the consequences of inflammation and resolving the disease itself. Learn more about our mission to restore natural healing:

Imagine waking up each day with the unpredictability of a storm brewing within your own body. This is the reality for many individuals living with Behçet’s Disease, a rare, chronic condition that manifests through inflammation in various parts of the body. The journey to understand and cope with this disease is marked by emotional highs and lows, scientific breakthroughs, and personal triumphs. #arthritis #osteoarthritis #osteoarthritistreatment #osteoarthritissupport #osteoarthritiscare #osteoarthritisawareness